Independent consulting on persistence-engineering claims in CAR-T programs. The 2024 FOXO1 evidence and four other major edits, synthesised into a working framework for platform, diligence, and partnership calls. Written by an independent analyst, not a marketing team.
Persistence engineering is the most consequential design space in CAR-T right now. Five edits — FOXO1, c-Jun, PD-1, TET2, DNMT3A — each promise durability, but each answers a different buyer or partner question. The brief separates what each edit does, what it does not do, and which decision it actually informs.
No sell-side bank backing. No vendor-funded white paper. No retained pharma client whose program is in the analysis. The word biotech operators and LPs use to distinguish honest reads from positioned ones.
A 5-edit decision matrix and a 12-question diligence pack. Built to answer: which edit fits which buyer, which claim survives diligence, which partner conversation each one supports.
Every load-bearing claim sourced to primary peer-reviewed literature or company filing. No aggregator citations, no conference abstracts cited as full papers. Disclosure-via-changelog discipline where rebuilds occur.
Scoped fixed-fee. Named-reader licensing rather than seat licences. Tiers 1–3 self-serve via Stripe; Tiers 4–5 invoiced after a scoping call. Classified as professional services for your finance team.
The flagship brief — CAR-T Persistence Engineering: A 2025 Landscape Brief — is structured to answer the question buyers actually have: which edit, for which buyer, on which decision. Not a literature survey; a decision framework with citations.
Cover, executive snapshot, the Three-Paradigm Divide, a §3 preview, and the full table of contents. Sent to your inbox — no follow-up sales sequence, no sharing of your address.
Productised tiers are pre-paid, scoped, fixed-fee — purchased directly via secure checkout. Custom engagements are scoped on a kickoff call before invoicing.
Launch price. Standard $349.
Save $99 vs separate purchase.
Launch price. Standard $2,500.
Mapped onto your specific pipeline.
These tiers begin with a kickoff call to scope the question, the deliverable, and the timeline. Pricing is fixed before invoicing — no hourly billing.
Delivered in 3 weeks. One revision round.
Three months. One team or one investor.
The brief is written by Dr Leon Xu — an independent researcher with a clinical (MD) and immunological (BSc Immunology & Microbiology) training base, working across the boundary where T-cell biology meets translational design.
The work is independent in a specific sense the buyers care about: not sell-side, not vendor-funded, not retained by a pharma client whose program is part of the analysis. Independence is the discipline that lets the brief say what does not work as cleanly as what does.
The corpus this advisory draws from spans T-cell transcription-factor biology (FOXO1, BATF–IRF4, TCF1, SOX13), CAR-T persistence-engineering, and the broader immune-architecture literature. Decision frameworks are tested against primary peer-reviewed sources before they enter a client deliverable.
Named-reader licensing means the engagement is licensed to a specified individual (Tier 1) or a specified group within a single company (Tier 2: up to 10; Tier 3: up to 25). It is the standard format for advisory work — clearer than the seat-licence language used for productised reports.
Sell-side bank reports are written for trading-flow audiences and reflect the bank's wider relationships. Vendor-funded white papers reflect the funder's positioning. Independent consulting is paid for entirely by the buyer of the analysis, with no third-party economic stake in the conclusion. That difference is the product.
Tiers 1–3 are framed around the persistence-engineering question. Tiers 4–5 are scoped to your specific question on a kickoff call before invoicing — typically build-vs-license, an investor diligence response, partner-pitch positioning, or a competitive read on a particular claim.
Professional services / advisory consulting. Each engagement is scoped, fixed-fee, and pre-paid (Tiers 1–3) or invoiced after scoping (Tiers 4–5). Stripe receipts and invoices are issued under Leon Xu trading as Fx Health · ABN 47 324 504 763.
Tier 1: full refund within 7 days of delivery if the brief does not meet the description on this page. Tier 2 / 3: equivalent satisfaction guarantee scoped on engagement start. Tier 4 includes one revision round; further revisions are scoped separately. Tier 5 includes ongoing analysis as part of the retainer scope.
Engagement details are confidential by default. NDAs are entertained for Tiers 3–5 on request. Aggregate insights from past engagements may inform future framework iterations, never specific client material.
Tier 1 is the natural entry point. If your team needs the framework on its own pipeline, Tier 2 or 3 is the right call.
Buy the brief — $249 USD